Drug delivery medical device
View Patent ↗Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on said substrate, wherein said coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within said coating and on said substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of said medical device in the body of said subject a portion of said pharmaceutical agent and/or active biological agent is delivered at said intervention site along with at least a portion of said polymer and/or a at least a portion of said pharmaceutical carrying agents.
1. A method comprising the steps of:
stimulating a substrate for 20 seconds or less to release at least about 35% of a coating on at least a portion of the substrate, the coating including a polymer and a crystalline pharmaceutical agent.
2. The method of claim 1 , wherein the substrate is a balloon.
3. The method of claim 2 , wherein the stimulation step includes inflating the balloon.
4. The method of claim 1 , wherein the pharmaceutical agent and the polymer are in the same layer, in separate layers, or form overlapping layers.
5. The method of claim 1 , wherein the coating includes a plurality of layers.
6. The method of claim 5 , wherein the plurality of layers comprise three layers deposited as follows:
a first polymer layer,
a first pharmaceutical agent layer, and
a second polymer layer.
7. The method of claim 1 , wherein the polymer is selected from the group consisting of non-absorbable and bioabsorbable polymer.
8. The method of claim 7 , wherein the wherein the bioabsorbable polymer includes between 1% and 95% glycolic acid content PLGA-based polymer.
9. The method of claim 7 , wherein the bioabsorbable polymer is selected from the group consisting of: Polylactides (PLA); PLGA (poly(lactide-co-glycolide); Polyanhydrides; Polyorthoesters; Poly(N-(2-hydroxypropyl) methacrylamide); DLPLA—poly(dl-lactide); LPLA—poly(l-lactide); PGA—polyglycolide; PDQ—poly(dioxanone); PGA-TMC—poly(glycolide-co-trimethylene carbonate); PGA-LPLA—poly(l-lactide-co-glycolide); PGA-DLPLA—poly(dl-lactide-co-glycolide); LPLA-DLPLA—poly(l-lactide-co-dl-lactide); and PDO-PGA-TMC—poly(glycolide-co-trimethylene carbonate-co-dioxanone), and combinations, copolymers, and derivatives thereof.
10. The method of claim 1 , wherein the pharmaceutical agent comprises a macrolide immunosuppressive drug.
11. The method of claim 10 , wherein the macrolide immunosuppressive drug comprises one or more of rapamycin, 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxy)propyl-rapamycin, 40-O-(6-Hydroxy)hexyl-rapamycin, 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin, 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin, 40-0-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin, 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin, 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), and 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus).
12. The method of claim 1 , wherein the pharmaceutical agent is rapamycin.
13. The method of claim 1 , wherein the pharmaceutical agent is at least 50% crystalline.
14. The method of claim 1 , wherein the pharmaceutical agent is at least 90% crystalline.
15. The method of claim 1 , wherein the coating is formed on said substrate by a process comprising at least one of: depositing a polymer by an e-RESS, an e-SEDS, or an e-DPC process, and depositing the pharmaceutical agent by an e-RESS, an e-SEDS, or an e-DPC process.
16. The device of claim 15 , wherein the process of forming the coating provides improves adherence of the coating to the substrate prior to deployment of the device and facilitates dissociation of said coating from said substrate upon stimulation.
17. The device of claim 1 , wherein the device is adapted to transfer less than about 10% of the coating absent stimulation of the coating.
18. A method comprising the steps of:
inflating a balloon for 20 seconds or less to release at least about 35% of a coating on at least a portion of the balloon, the coating including a bioabsorbable polymer and a crystalline pharmaceutical agent.
19. The method of claim 18 , wherein the bioabsobable polymer is PLGA and the pharmaceutical agent is rapamycin.
20. The method of claim 19 , wherein the coating includes three layers deposited as follows:
a first PLGA layer,
a first rapamycin layer, and
a second PLGA layer.
21. A method comprising the steps of:
providing a balloon having a coating including three polymer layers and two crystalline pharmaceutical agent layers; and
inflating the balloon for at most 19seconds to release at least about 35% of the coating.